About the Company
We do not have any company description for Solid Biosciences Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Solid Biosciences Inc.
Solid Biosciences Inc. Included in Nasdaq Biotechnology Index ...
Solid Biosciences Inc., a company specializing in precision genetic medicines for neuromuscular and cardiac diseases, announced its inclusion in the Nasdaq Biotechnology Index, effective December ...
Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates
Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to ...
Solid Biosciences Positioned For Next-Gen Duchenne Muscular ... - Benzinga
Solid Biosciences ended Q3 2024 with $171.1 million in cash, securing operations through 2026. Initial Phase 1/2 trial results for SGT-003 in DMD expected in Q1 2025. Geopolitical tensions, Fed ...
Solid Biosciences Provides First Quarter 2024 Business Update and ...
CHARLESTOWN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases ...
27,100 Shares in Solid Biosciences Inc. (NASDAQ:SLDB) Acquired by ...
Solid Biosciences Inc. has a one year low of $2.41 and a one year high of $10.37. The business’s fifty day moving average is $5.14 and its 200 day moving average is $4.25.
Solid Biosciences Inc.: Solid Biosciences Added to the Nasdaq ...
CHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for ...
Solid Biosciences Inc. Research & Ratings | SLDB | Barron's
Solid Biosciences Inc. research and ratings by Barron's. View SLDB revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.
Solid Biosciences Inc. Stock Grades | SLDB | Barron's
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for ...
Analysts Are Updating Their Solid Biosciences Inc. (NASDAQ:SLDB ...
Investors in Solid Biosciences Inc. (NASDAQ:SLDB) had a good week, as its shares rose 5.5% to close at US$0.80 following the release of its second-quarter results. Sales greatly exceeded ...
Solid Biosciences Provides Third Quarter 2022 Business Update and ...
FINN Partners 212-867-1768 David.Carey@finnpartners.com Media Contact: Erich Sandoval FINN Partners 917-497-2867 Erich.Sandoval@finnpartners.com Source: Solid Biosciences Inc. 2022 GlobeNewswire, Inc.
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy ...
Solid Biosciences ended the third quarter of 2024 with approximately $171.1 million in cash, cash equivalents, and available-for-sale securities, with an anticipated cash runway into 2026.
Similar Companies
Loading the latest forecasts...